
pt
see support solid outlook
room margin improv despit price
headwind risk/reward approv remain
favor reiter posit rate
strong start year consist view improv fundament
favor posit rel peer includ invest theme report
continu streak approv difficult-to-formul gener need
upsid see ampl shot goal addit see solid margin gain launch
mix fx like outpac price headwind
multipl modestli increas earn appropri view
progress difficult-to-formul gener appli multipl upsid scenario
see bln ebitda impli contract downsid
bln impli
 maintain ep consensu recent
rx trend sandoz result earli gener copaxon uptak make us slightli
cautiou revenu
revenu bln bln ebitda bln bln ep
includ recent buy-back may requir gener advair/restasi approv
includ advair see meaning upsid best case trim
revenu slightli cautiou view us gener partial off-set fx tailwind
rangeofresult tend offer robust guidanc optimist top end us
trim price pressur drove revenu low end
higher margin launch outperform impli ep
continu next page
copaxon uptak advair insulin gener
see downsid price pressur launch delay
susquehanna intern group llp compris affili entiti includ susquehanna financi group lllp sfg sfg provid research execut
servic sfg member finra sfg seek busi compani cover research report result investor awar firm may
conflict interest could affect object report pleas see import disclosur page
continu previou page
margin expans driven product mix increment cautiou base us gener price/volum
pressur copaxon launch rx uptak encourag potenti higher margin estrac even
ipxl enter fx tailwind total rx volum pretti im show y/i declin
howev see suggest portfolio ration improv mix appear let go share
high volum product price deterior assum margin well averag
neg amlodipin biggest rx loser q/q im sale per rx use im sale
rough proxi estim base us gener ex-epipen ex-copaxon could essenti flat despit
rx declin portfolio ration may mitig price eros look addit color
capac plan abil begin stabil base
impact convert debt net tax
numer dilut ep
good sold
good sold
good sold
contribut product launch individu calendar year exclud includ key product product
price target base ev/ebitda bln view multipl
appropri consid peer trade signific opportun complex generics/
biosimilar diversif ex-u exposur also challeng us price environ also
repres price-to-earnings toward lower end histor rang
key risk stock includ achiev approv share complex gener off-set impact
heighten price pressur base portfolio improv margin resolv legal/regulatory/reput
issu relat epipen potenti price pressur continu even acceler variou market
competit government-impos price reduct includ condit deterior
last year compani success challeng patent brand drug success defend
intellectu properti myl brand drug especi epipen compani abil continu manag
debt potenti take advantag busi develop opportun continu success
oper compani global commerci platform suppli chain drive revenu growth improv
margin bring acquir busi compani global qualiti standard resolv issu
nashik india manufactur plant potenti tax reform affect treatment foreign-domicil
compani achiev tax benefit deal potenti use take-over defens
block sale compani view stakehold consider includ creation sticht
see downsid addit global price pressur reduc earn
prevent multipl expans current year ebitda
andrew finkelstein herebi certifi view us express research report accur reflect respect person view subject
secur issuer also certifi part respect compens directli indirectli relat specif recommend view
express research report
sfg market maker secur inc
susquehanna intern group llp compris number trade invest relat entiti common control includ susquehanna financi
group lllp sfg affili and/or princip may long short posit secur relat issu mention capac specialist and/
market maker may execut order princip basi subject secur inform present sourc believ reliabl guarante
accur complet past perform taken indic guarante futur result hyperlink provid report conveni pleas
awar product inform suppli hyperlink page endors approv sfg
follow data element report sourc bloomberg lp price yesterday close high low share outstand averag daili trade
volum volum contract other specif sourc
sfg employ follow rate system
posit expect stock appreci least next month
neutral expect stock perform within rang percentag point next month
neg expect stock depreci least next month
suspend previous publish rate and/or estim current suspend review
prior juli rate system also requir /- expect return month initi positive/neg rate
grossdebt preferredtev gross debt prefer total enterpris valu express
netdebt/ebitda net debt gross debt less cash hand ebitda forward year ebitda estim
yield yield fulli dilut share outstanding/curr share price express
ytm yield-to-matur ytm impli bond outstand due year closest express
us treasuri yield express
volum averag option contract volum symbol
skewrank current day skew valu compar past year worth skew valu rank current day valu past year calcul previou
trade day includ last trade day
impliedvolatil impli volatil at-the-forward volatil level impli market option price day impli volatil specif time frame
select alway present annual standard deviat
realizedvolatil realiz volatil financi instrument day gener measur calcul determin averag deviat
averag price financi instrument given time period measur frequent compar impli volatil determin option price over-
under-valued also known histor volatil
cover compani categori
proprietari sfg product prepar intend sole use sophist profession institut trader manag gener
invest public unauthor redistribut report mean repres violat us copyright law could result legal action suspens
intend recipi privileg question regard transmiss pleas contact inform commun
intend distribut use person entiti jurisdict countri distribut use would contrari law regul
would subject susquehanna financi group lllp affili registr requir within jurisdict countri
invest bank client categori
rate price target histori inc
